Ubrelvy Tablet
Product Images NDC 0023-6501

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Ubrelvy (NDC 0023-6501). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Allergan, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

The Following Structural Formula For Ubrelvy Is Ubrogepant, A Calcitonin Gene-related Peptide (cgrp) Receptor Antagonist. The Chemical Name Of Ubrogepant Is (3's)-n-((3s,5s,6r)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl)-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide. (Ubrelvy 01)

FDA Label Image

Figure 1: Percentage Of Patients Achieving Pain Freedom Within 2 Hours In Pooled Studies 1 And 2 (Ubrelvy 02)

The text describes a graph displaying the percentage of individuals achieving pain freedom over time in hours from dose. The graph includes three data points at 60%, 80%, and 100%, as well as a fourth point labeled "409". The x-axis represents time in hours from the dose, ranging from 1 hour to 15 hours. There are two lines on the graph representing the medications UBRELVY 100 mg and UBRELVY 50 mg, as well as a line for the placebo group.*

FDA Label Image

Figure 2: Percentage Of Patients Achieving Mbs Freedom Within 2 Hours In Pooled Studies 1 And 2 (Ubrelvy 03)

This appears to be a chart showing the effectiveness of UBRELVY, a medication available in 50 mg and 100 mg doses, compared to a placebo. The chart shows the percentage of people achieving a desired outcome over time after taking the medication or placebo. However, without knowing the desired outcome or more context, it's difficult to provide a more detailed description.*

FDA Label Image

Allergan (Ubrelvy 05)

FDA Label Image

Ndc 0023-6498-02ubrelvy(ubrogepant) Tablet50 mgrx Onlycontains 1 Tablet (Ubrelvy 06)

This is a description of UBRELVY® medication, which comes in tablets format of 50 mg of brogepant. It warns to keep the medication out of reach of children and provides storage instructions (between 20°C and 25°C). The text also indicates to refer to the package insert for more information and mentions a lot number of MY 12345.*

FDA Label Image

Ndc 0023-6498-02ubrelvy(ubrogepant) Tablet50 mgrx Onlycontains 1 Tablet (Ubrelvy 07)

UBRELVY is a medication available in tablet form, containing the active ingredient Ubrogepant. No additional information is available due to the limited text provided.*

FDA Label Image

Ndc 0023-6498-10ubrelvy(ubrogepant) Tablets50 mgrx Onlycontains 10 Tablets (Ubrelvy 08)

FDA Label Image

Ndc 0023-6498-16ubrelvy(ubrogepant) Tablets50 mgrx Onlycontains 16 Tablets (Ubrelvy 09)

UBRELVY is a type of medication that comes in tablet form and contains ubrogepant. Unfortunately, the results are incomplete and not correct, so additional information cannot be provided.*

FDA Label Image

Ndc 0023-6498-30ubrelvy(ubrogepant) Tablets50 mgrx Onlycontains 30 Tablets (Ubrelvy 0a)

UBRELVY® is a prescription medication available in 100 mg tablets. It is manufactured by Forest Laboratories and should be stored between 20°C and 25°C (68°F and 77°F). The LOT number for this medication is 12345.*

FDA Label Image

Ndc 0023-6501-02ubrelvy(ubrogepant) Tablet100 mgrx Onlycontains 1 Tablet (Ubrelvy 0b)

FDA Label Image

Ndc 0023-6501-02ubrelvy(ubrogepant) Tablet100 mgrx Onlycontains 1 Tablet (Ubrelvy 0c)

FDA Label Image

Ndc 0023-6501-10ubrelvy(ubrogepant) Tablets100 mgrx Onlycontains 10 Tablets (Ubrelvy 0d)

This is not-available as the text only contains jumbled words and characters.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.